Century Therapeutics (IPSC) CEO reports 463-share tax withholding on RSU vesting
Rhea-AI Filing Summary
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, 463 shares of common stock were withheld by the company at $2.56 per share to satisfy tax withholding obligations. This was not an open-market sale. After this withholding, he directly holds 3,766,355 shares of Century Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 463 shares
Net Sell
1 txn
Insider
Pfeiffenberger Brent
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 463 | $2.56 | $1K |
Holdings After Transaction:
Common Stock — 3,766,355 shares (Direct)
Footnotes (1)
- F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
FAQ
What insider transaction did Century Therapeutics (IPSC) report for its CEO?
Century Therapeutics reported that President and CEO Brent Pfeiffenberger had 463 common shares withheld to cover tax obligations upon RSU vesting. This Form 4 event reflects administrative tax withholding, not an open-market stock sale or purchase.
What does the F transaction code mean in the IPSC CEO’s Form 4?
The F code indicates shares were disposed of to pay an exercise price or tax liability. For Century Therapeutics, 463 CEO shares were withheld by the issuer to satisfy RSU-related tax obligations, classifying this event as tax withholding rather than a typical market sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.